Navigation Links
New Anti-Clotting Drug Less Risky For Heart Attack Patients

A new study has found anti-clotting drug called bivalirudin (Angiomax) that beats the standard combination drug therapy for patients with acute coronary syndromes such as heart// attacks. This new blood thinner seems to be less risky for patients suffering from acute coronary syndromes.

The Results of the ‘Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial’ were published in November issue of the New England Journal of Medicine. The Medicines Company and Nycomed, which market Angiomax, funded the study. A team lead by Dr. Gregg W. Stone, a professor of medicine and director of cardiovascular research and education are conducting the research.

Dr. Stone said: "We use bivalirudin at Columbia in the vast majority of cases and have found out that compared to heparin, it is just as effective and safely allows us to do angioplasty with a major reduction in bleeding episodes."

The journal described a trial that involved around 14,000 patients with heart attack or other acute coronary syndromes. The patients were assigned to one of three drug regimens: a package treatment including heparin; a similar package including bivalirudin; or bivalirudin alone. The results showed that the patients treated with Angiomax, also known as bivalirudin, had similar rates of serious complications, such as death, heart attack and repeat artery clearing procedures as the other groups, but had significantly lower rates of serious bleeding.

Only 3 percent of those getting bivalirudin alone had major bleeding episodes comparing to that of 5.7 percent of those getting the heparin package, for patients, that makes all the difference, Stone said. Moreover, the researchers were able find that the incidences of artery blockages or major bleeding were also reduced by the usage of bivalirudin by about 14 percent compared to a drug package including heparin.

"The big difference was the reduction of major bleeding, almost 50 percent," Stone added. "Major bleeding has been associated with higher mortality, so it is important that bivalirudin, which reduced the risk of major bleeding up to 47 percent, could be reserved for patients with history of bleeding such as anemia.” – He added.

To conclude, the drug has been currently approved as a replacement for heparin in all nonemergency angioplasty procedures.

Related medicine news :

1. FDA Approves New Anti-Clotting Drug
2. Herbal Remedy Risky for Cancer Patients
3. Risky Drugs To Be Avoided In The Elderly
4. HRT Not That Risky For Breast Cancer
5. Coffee In Pregnancy May Be Risky: Study
6. Distinct Brain Sections Are Activated While Making Risky Decisions
7. Americans Avoiding Risky Foods
8. Heavy Dosage Of Vitamin Supplements May Be Risky For Pregnant Women
9. Males Show More Risky Behaviour with Alcohol
10. Risky Behavior In Teenagers Leads To Depression
11. Insight Into The Risky Health Decisions On Bird Flu
Post Your Comments:

(Date:10/12/2017)... ... , ... The American College of Medical Informatics (ACMI) will present the 2017 ... Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is ... pioneer in the field of medical informatics, this prestigious award is presented to an ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... Restoration, has recently contributed a medical article to the newly revamped Cosmetic ... Mohebi’s article spotlights the hair transplant procedure known as Follicular Unit Extraction ...
(Date:10/12/2017)... , ... October 12, 2017 , ... On Saturday, October ... treadmill relay – Miles by Moonlight to raise money for the American Heart Association ... more. , Teams will work together to keep their treadmills moving for 5 ...
(Date:10/12/2017)... ... 2017 , ... In the United States, single-family home owners ... New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, and California—the average is $7,000 ... property-tax rates, which contributes to the relatively lower cost of living in places ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vodori, ... Flow promotional review platform at the Promotional Review Committee Compliance and Best ... marketers streamline the medical, legal, and regulatory review (MLR) process – which ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... , Oct. 12, 2017 AVACEN Medical , ... company with their  2017 New Product Innovation Award for ... extensive primary and secondary medical device market research by Frost ... its first-to-market OTC, drug-free pain relief product, the AVACEN 100, ... to treating fibromyalgia widespread pain. ...
(Date:10/12/2017)... Pa. , Oct. 12, 2017 ... leader in innovative solutions for injectable drug administration, today ... before the market opens on Thursday, October 26, 2017, ... the results and business expectations at 9:00 a.m. Eastern ... (U.S.) or 253-336-8738 (International). The conference ID is 94093362. ...
(Date:10/11/2017)... Oct. 11, 2017  Caris Life Sciences ® , ... the promise of precision medicine, today announced that St. ... Precision Oncology Alliance™ (POA) as its 17 th ... St. Jude Crosson Cancer Institute will help develop standards ... of tumor profiling, making cancer treatment more precise and ...
Breaking Medicine Technology: